Georgios Tsivgoulis1, Vasileios-Arsenios Lioutas2, Panayiotis Varelas2, Aristeidis H Katsanos2, Nitin Goyal2, Robert Mikulik2, Kristian Barlinn2, Christos Krogias2, Vijay K Sharma2, Konstantinos Vadikolias2, Efthymios Dardiotis2, Theodore Karapanayiotides2, Alexandra Pappa2, Christina Zompola2, Sokratis Triantafyllou2, Odysseas Kargiotis2, Michael Ioakeimidis2, Sotirios Giannopoulos2, Ali Kerro2, Argyrios Tsantes2, Chandan Mehta2, Mathew Jones2, Christoph Schroeder2, Casey Norton2, Anastasios Bonakis2, Jason Chang2, Anne W Alexandrov2, Panayiotis Mitsias2, Andrei V Alexandrov2. 1. From the Department of Neurology (G.T., N.G., A.K., J.C., A.W.A., A.V.A.), University of Tennessee Health Science Center, Memphis; Second Department of Neurology (G.T., A.H.K., C.Z., S.T., M.I., A.B.), "Attikon" Hospital, School of Medicine, National and Kapodistrian University of Athens, Greece; Department of Neurology (V.-A.L., C.N.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurology (P.V., C.M., M.J., P.M.), Henry Ford Hospital, Detroit, MI; Department of Neurology (A.H.K., S.G.), University of Ioannina School of Medicine, Greece; International Clinical Research Center (R.M.), Neurology Department, St. Anne's Hospital and Masaryk University, Brno, Czech Republic; Department of Neurology (K.B.), Dresden University Stroke Center; Department of Neurology (C.K., C.S.), St. Josef-Hospital, Ruhr University of Bochum, Germany; Division of Neurology (V.K.S.), Yong Loo Lin School of Medicine, National University of Singapore; Department of Neurology (K.V.), Democritus University of Thrace, Alexandroupolis, Greece; Department of Neurology (E.D., A.P.), University of Thessaly, Larissa; Second Department of Neurology (T.K.), AHEPA University Hospital, Aristotelian University of Thessaloniki; Acute Stroke Unit (O.K.), Metropolitan Hospital, Piraeus; Laboratory of Haematology and Blood Bank Unit (A.T.), "Attikon" Hospital, School of Medicine, National and Kapodistrian University of Athens, Greece; Australian Catholic University (A.W.A.), School of Nursing, Sydney, Australia; and Department of Neurology (P.M.), University of Crete, Heraklion, Greece. tsivgoulisgiorg@yahoo.gr. 2. From the Department of Neurology (G.T., N.G., A.K., J.C., A.W.A., A.V.A.), University of Tennessee Health Science Center, Memphis; Second Department of Neurology (G.T., A.H.K., C.Z., S.T., M.I., A.B.), "Attikon" Hospital, School of Medicine, National and Kapodistrian University of Athens, Greece; Department of Neurology (V.-A.L., C.N.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurology (P.V., C.M., M.J., P.M.), Henry Ford Hospital, Detroit, MI; Department of Neurology (A.H.K., S.G.), University of Ioannina School of Medicine, Greece; International Clinical Research Center (R.M.), Neurology Department, St. Anne's Hospital and Masaryk University, Brno, Czech Republic; Department of Neurology (K.B.), Dresden University Stroke Center; Department of Neurology (C.K., C.S.), St. Josef-Hospital, Ruhr University of Bochum, Germany; Division of Neurology (V.K.S.), Yong Loo Lin School of Medicine, National University of Singapore; Department of Neurology (K.V.), Democritus University of Thrace, Alexandroupolis, Greece; Department of Neurology (E.D., A.P.), University of Thessaly, Larissa; Second Department of Neurology (T.K.), AHEPA University Hospital, Aristotelian University of Thessaloniki; Acute Stroke Unit (O.K.), Metropolitan Hospital, Piraeus; Laboratory of Haematology and Blood Bank Unit (A.T.), "Attikon" Hospital, School of Medicine, National and Kapodistrian University of Athens, Greece; Australian Catholic University (A.W.A.), School of Nursing, Sydney, Australia; and Department of Neurology (P.M.), University of Crete, Heraklion, Greece.
Abstract
OBJECTIVE: To compare the neuroimaging profile and clinical outcomes among patients with intracerebral hemorrhage (ICH) related to use of vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) for nonvalvular atrial fibrillation (NVAF). METHODS: We evaluated consecutive patients with NVAF with nontraumatic, anticoagulant-related ICH admitted at 13 tertiary stroke care centers over a 12-month period. We also performed a systematic review and meta-analysis of eligible observational studies reporting baseline characteristics and outcomes among patients with VKA- or DOAC-related ICH. RESULTS: We prospectively evaluated 161 patients with anticoagulation-related ICH (mean age 75.6 ± 9.8 years, 57.8% men, median admission NIH Stroke Scale [NIHSSadm] score 13 points, interquartile range 6-21). DOAC-related (n = 47) and VKA-related (n = 114) ICH did not differ in demographics, vascular risk factors, HAS-BLED and CHA2DS2-VASc scores, and antiplatelet pretreatment except for a higher prevalence of chronic kidney disease in VKA-related ICH. Patients with DOAC-related ICH had lower median NIHSSadm scores (8 [3-14] vs 15 [7-25] points, p = 0.003), median baseline hematoma volume (12.8 [4-40] vs 24.3 [11-58.8] cm3, p = 0.007), and median ICH score (1 [0-2] vs 2 [1-3] points, p = 0.049). Severe ICH (>2 points) was less prevalent in DOAC-related ICH (17.0% vs 36.8%, p = 0.013). In multivariable analyses, DOAC-related ICH was independently associated with lower baseline hematoma volume (p = 0.006), lower NIHSSadm scores (p = 0.022), and lower likelihood of severe ICH (odds ratio [OR] 0.34, 95% confidence interval [CI] 0.13-0.87, p = 0.025). In meta-analysis of eligible studies, DOAC-related ICH was associated with lower baseline hematoma volumes on admission CT (standardized mean difference = -0.57, 95% CI -1.02 to -0.12, p = 0.010) and lower in-hospital mortality rates (OR = 0.44, 95% CI 0.21-0.91, p = 0.030). CONCLUSIONS: DOAC-related ICH is associated with smaller baseline hematoma volume and lesser neurologic deficit at hospital admission compared to VKA-related ICH.
OBJECTIVE: To compare the neuroimaging profile and clinical outcomes among patients with intracerebral hemorrhage (ICH) related to use of vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) for nonvalvular atrial fibrillation (NVAF). METHODS: We evaluated consecutive patients with NVAF with nontraumatic, anticoagulant-related ICH admitted at 13 tertiary stroke care centers over a 12-month period. We also performed a systematic review and meta-analysis of eligible observational studies reporting baseline characteristics and outcomes among patients with VKA- or DOAC-related ICH. RESULTS: We prospectively evaluated 161 patients with anticoagulation-related ICH (mean age 75.6 ± 9.8 years, 57.8% men, median admission NIH Stroke Scale [NIHSSadm] score 13 points, interquartile range 6-21). DOAC-related (n = 47) and VKA-related (n = 114) ICH did not differ in demographics, vascular risk factors, HAS-BLED and CHA2DS2-VASc scores, and antiplatelet pretreatment except for a higher prevalence of chronic kidney disease in VKA-related ICH. Patients with DOAC-related ICH had lower median NIHSSadm scores (8 [3-14] vs 15 [7-25] points, p = 0.003), median baseline hematoma volume (12.8 [4-40] vs 24.3 [11-58.8] cm3, p = 0.007), and median ICH score (1 [0-2] vs 2 [1-3] points, p = 0.049). Severe ICH (>2 points) was less prevalent in DOAC-related ICH (17.0% vs 36.8%, p = 0.013). In multivariable analyses, DOAC-related ICH was independently associated with lower baseline hematoma volume (p = 0.006), lower NIHSSadm scores (p = 0.022), and lower likelihood of severe ICH (odds ratio [OR] 0.34, 95% confidence interval [CI] 0.13-0.87, p = 0.025). In meta-analysis of eligible studies, DOAC-related ICH was associated with lower baseline hematoma volumes on admission CT (standardized mean difference = -0.57, 95% CI -1.02 to -0.12, p = 0.010) and lower in-hospital mortality rates (OR = 0.44, 95% CI 0.21-0.91, p = 0.030). CONCLUSIONS:DOAC-related ICH is associated with smaller baseline hematoma volume and lesser neurologic deficit at hospital admission compared to VKA-related ICH.
Authors: Małgorzata M Miller; Jessica Lowe; Muhib Khan; Muhammad U Azeem; Susanne Muehlschlegel; Adalia H Jun-O'Connell; Richard P Goddeau; Majaz Moonis; Danielle Gritters; Brian Silver; Nils Henninger Journal: Neurocrit Care Date: 2019-08 Impact factor: 3.210
Authors: Andrew M Demchuk; Patrick Yue; Elena Zotova; Juliet Nakamya; Lizhen Xu; Truman J Milling; Tomoyuki Ohara; Joshua N Goldstein; Saskia Middeldorp; Peter Verhamme; Jose Luis Lopez-Sendon; Pamela B Conley; John T Curnutte; John W Eikelboom; Mark Crowther; Stuart J Connolly Journal: Stroke Date: 2021-05-10 Impact factor: 10.170